Patent Application
20130237709
This Application claims the benefit of priority from Italian Patent Application Nos. MI2012A000329, filed Mar. 2, 2012 and MI12012A000589, filed Apr. 12, 2012, the contents of each of which are incorporated herein by reference.
The present invention relates to new intermediates useful for the synthesis of fexofenadine, processes for their preparation and their conversion to fexofenadine.
Fexofenadine is a so-called “second generation” oral antihistamine agent, devoid of side effects, used for treating the symptoms of allergic reactions, symptoms related to the release of histamine. Histamine is one of the chemical mediators of inflammation, deriving from the decarboxylation of histidine by histidine decarboxylase. Antihistamine agents inhibit the activity of H1 histamine receptors, mainly present in the skin and in the bronchi, by blocking histamine release. The contact of an allergen (a substance which can cause allergic symptoms) with H1 histamine receptors stimulates the release of histamine, causing capillary dilatation, capillary permeability and vasodilatation, then causing local erythemas, local edemas (swellings) and rashes. Furthermore, following histamine release, itching and, in predisposed subjects, severe bronchoconstrictions, gastroenteric mobility and an increase of salivary and bronchial gland secretion may occur.
Fexofenadine is the carboxylic acid corresponding to terfenadine, of which is the main metabolite. However, fexofenadine does not show the cardiotoxic effects of terfenadine and, thanks to the fact that it does not cross the blood-brain barrier, it does not cause to the patient those side effects typical of the so-called “first generation” antihistamine agents, such as sleepiness and tiredness. Fexofenadine is the compound of formula (I)
chemically known as 2-[4-[1-hydroxy-4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]butyl]phenyl]-2-methyl-propanoic acid, described in U.S. Pat. No. 4,254,129 and sold under the trademark Allegro®.
WO 02/10115 (Texcontor Etablissement) discloses a process for the synthesis of fexofenadine comprising the reaction of the compound of formula (II)
with a copper or silver compound, in particular copper(II)oxide in the presence of palladium, or of a compound containing palladium, to give the intermediate of
CN 102079708 (Zhejiang Giming Pharmaceutical Co ltd) discloses a process for the synthesis of fexofenadine comprising the preparation of the compound of formula (IV)
by reacting the intermediate of formula (II) with a mercury(II)compound, in particular mercury(II)oxide.
Both processes are characterized by the use of expensive and difficult to handle reagents, because of their high toxicity by inhalation, contact with the skin and ingestion, and of their high damaging action to the environment.
We have now found new compounds which are useful intermediates for the synthesis of fexofenadine and which do not require the use of toxic reagents such as mercury salts or expensive reagents such as palladium salts and which allow to use easy handling reaction conditions with low environmental impact.
Therefore, an object of the present invention are the compounds of formula (V)
wherein
A preferred object of the present invention are the compounds of formula (Va)
wherein
In particular, a still more preferred object of the present invention is a compound of formula (Vb)
The compounds of formula (V), (Va) and (Vb) are new and are useful intermediates for the synthesis of fexofenadine.
A further object of the present invention is a process for the synthesis of the compounds of formula (V), preferably (Va), comprising the dissolution of the intermediates of formula (IIa)
wherein R1 is a linear or branched C1-C20 alkyl group and R4 is a halogen or a hydroxy group, in an alcoholic solvent and the subsequent reaction with a Brønsted acid, or a Lewis acid, or mixtures thereof, at a temperature from 25° C. to the reflux temperature of the solvent for a time sufficient to form the desired compounds which are recovered using known techniques,
The alcoholic solvent is a linear or branched C1-C4 alcohol, preferably selected from among methanol, ethanol, isopropanol and butanol. Methanol is preferably used.
The Brønsted acid is preferably selected from among hydrochloric acid, hydrobromic acid, sulfuric acid.
The Lewis acid is preferably selected from among zinc salts, preferably bromide, chloride, oxide, acetate, sulfate.
Preferably, a mixture of a Brønsted acid and a Lewis acid, still more preferably a mixture of hydrochloric acid and zinc chloride, is used.
The amount of hydrochloric acid is from about 1 to about 5 equivalents and the amount of zinc chloride is from about 1 and about 5 equivalents. About 2 equivalents of hydrochloric acid and about 3 equivalents of zinc chloride are preferably used.
The compounds of formula (V) can also be prepared starting from an intermediate of formula (VI)
wherein R1 is a linear or branched C1-C20 alkyl group and R4′ is a halogen atom, preferably chlorine or bromine.
A further object of the present invention is a process for the preparation of the compounds of formula (VI) starting from a compound of formula (IIa) according to the following scheme:
wherein
Suitable hydrogen halide solutions are a solution of hydrobromic acid in acetic acid and an aqueous hydrochloric acid solution.
A preferred embodiment of the present invention is the synthesis of the compound of formula (Vb)
comprising the dissolution of the intermediate of formula (H)
in methanol and the subsequent addition of zinc chloride and hydrochloric acid, at the reflux temperature of the solvent.
A further preferred embodiment of the present invention is the synthesis of a compound of formula (VIa)
wherein
by reaction with a hydrobromic acid or hydrochloric acid solution in a suitable solvent at a temperature from 30° C. to 50° C.
A further object of the present invention is a process for the synthesis of fexofenadine, starting from intermediates of formula (V), comprising:
The intermediates of formula (VI) and their transformation into fexofenadine are described, for example, in U.S. Pat. No. 6,147,216, the disclosure of is which is incorporated herein by reference.
Fexofenadine is preferably prepared starting from intermediates of formula (Va).
A further object of the present invention is a process for the synthesis of fexofenadine starting from intermediates of formula (VI), comprising:
The starting intermediate (VI) can be prepared from a compound of formula (Va) by reaction with aqueous hydrobromic acid or acetic acid in a suitable solvent, preferably toluene, or from a compound of formula (IIa) by reaction with a hydrohalide acid solution in a suitable solvent as above described.
The transformation of compounds (VIII) into fexofenadine is carried out according to the method described in WO 2011/158262, the contents of which are incorporated herein by reference, in the name of the Applicant.
When the saponification reaction is not carried out in step b) of the process object of the present invention, said reaction can be carried out in one of the subsequent steps c) and d). The saponification reaction is carried out according to known techniques, preferably in the presence of sodium or potassium hydroxide in methanol.
The trialkylorthoformate in step a) is selected from among trimethylorthoformate, triethylorthoformate or triisopropylorthoformate. Trimethylorthoformate is preferably used.
The alcoholic solvent is a linear or branched C1-C4 alcohol, preferably selected from among methanol, ethanol, isopropanol, butanol. Methanol is preferably used.
The acid catalyst in step a) is preferably selected from sulfuric acid, camphorsulfonic acid and methansulfonic acid. Camphorsulfonic acid is preferably used.
The solvent in step b) is preferably selected from among toluene, acetonitrile, tetrahydrofuran. Toluene is preferably used.
The base is preferably selected from among sodium bicarbonate, potassium bicarbonate, triethylamine. Sodium bicarbonate is preferably used.
The aqueous acid in step c) is preferably selected from among sulfuric acid, hydrochloric acid. Sulfuric acid is preferably used.
The solvent in step c) is preferably selected from among methanol, ethanol, isopropanol. Methanol is preferably used.
A preferred embodiment of the process object of the present invention is a process for the synthesis of fexofenadine starting from intermediates of formula (VIa),
wherein R4′ is a halogen atom;
comprising:
and
The transformation of compounds (VIIIa) into fexofenadine is carried out according to the method described in WO 2011/158262 in the name of the Applicant.
The trialkylorthoformate in step a′) is selected from among trimethylorthoformate, triethylorthoformate or triisopropylorthoformate. Trimethylorthoformate is preferably used.
The alcoholic solvent is a linear or branched C1-C4 alcohol, preferably selected from among methanol, ethanol, isopropanol, butanol. Methanol is preferably used.
The acid catalyst in step a′) is preferably selected from sulfuric acid, camphorsulfonic acid and methansulfonic acid. Camphorsulfonic acid is preferably used.
The advent in step b′) is preferably selected from among toluene, acetonitrile, tetrahydrofuran. Toluene is preferably used.
The base is preferably selected from among sodium bicarbonate, potassium bicarbonate, triethylamine. Sodium bicarbonate is preferably used.
The aqueous acid in step c′) is preferably selected from among sulfuric acid, hydrochloric acid. Sulfuric acid is preferably used.
The solvent in step c′) is preferably selected from among methanol, ethanol, isopropanol. Methanol is preferably used.
A still more preferred embodiment of the present invention is a process for the preparation of fexofenadine comprising:
The trialkylorthoformate in step 1) is selected from among trimethylorthoformate, triethylorthoformate or triisopropylorthoformate. Trimethylorthoformate is preferably used.
The alcoholic solvent is a linear or branched C1-C4 alcohol, preferably selected from among methanol, ethanol, isopropanol, butanol. Methanol is preferably used.
The acid catalyst in step 1) is preferably selected from sulfuric acid, camphorsulfonic acid and methansulfonic acid. Camphorsulfonic acid is preferably used.
The solvent in step 2) is preferably selected from among toluene, acetonitrile, tetrahydrofuran. Toluene is preferably used.
The base is preferably selected from among sodium bicarbonate, potassium bicarbonate, triethylarnine. Sodium bicarbonate is preferably used.
The saponification reaction is preferably carried out in the presence of sodium or potassium hydroxide in a solvent selected from among methanol, ethanol, isopropanol. Methanol is preferred.
The aqueous acid in step 4) is preferably selected from among sulfuric acid, hydrochloric acid. Hydrochloric acid is preferably used.
The solvent in step 4) is preferably selected from among methanol, ethanol, isopropanol. Methanol is preferably used.
The compounds (Vd), (VIIa) and (VIIc)
wherein R4′ is a halogen atom, preferably chlorine or bromine, are new and a preferred object of the present invention.
All the terms used in the present description, unless otherwise indicated, are intended in their common meaning as known in the art. Other more specific definitions for some terms, as used in the present context, are underlined herein after and constantly apply in the whole description and claims, unless a different definition explicitly provides for a broader definition.
The term “alkyl” refers to a linear or branched hydrocarbon, containing from 1 to 20 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, nm pentyl, n-hexyl, etc. A preferred alkyl group of the present invention is n-butyl.
Although the present invention has been described in its characterizing features, changes and equivalents which are obvious to the skilled in the art are included in the present invention.
Herein after, the present invention will be illustrated by some examples which are not intended to limit the scope of the invention.
In a reaction flask 10 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.04 mol), 30 ml methanol, 16.6 g zinc chloride (0.12 mol) were charged and the reaction mixture was kept under stirring up to complete dissolution. Then, 27 ml hydrochloric acid 3M in methanol (0.08 mol) were added and the reaction mixture was heated to the reflux temperature and kept under these conditions for six hours. At the end of the reaction, the temperature was brought to 15° C., a 30% ammonia solution was added up to pH 8 and the resultant solid was filtered. To the mother liquor 100 ml toluene were added, the mixture was washed with water (2×20 ml) and the collected organic phases were concentrated to residue by distillation under vacuum to give 10 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2-methyl-propanoate.
1H-NMR (CDCl3, 300 MHz): δ 7.90 (d, 2H), 7.36 (d, 2H), 3.61 (s, 3H), 3.41 (t, 2H), 3.28 (s, 3H), 3.00 (t, 2H), 1.96 (m, 2H), 1.55 (s, 6H).
13C-NMR (CDCl3, 300 MHz): δ 195.50 (C), 176.64 (C), 149.88 (C), 135.55 (C), 128.66 (CH), 125.99 (CH), 71.79 (CH2), 58.54 (CH3), 52.37 (CH3), 46.87 (C), 35.09 (CH2), 26.44 (CH3), 24.20 (CH2).
MS (m/e): 246.1 (M-CH3OH), 220.1, 205.1, 161.1 (100%), 146.1, 131.1, 118.1.
In a reaction flask 1.0 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.004 mol), 5 ml methanol, 1.68 g zinc chloride (0.01 mol) were charged and the reaction mixture was kept under stirring up to complete dissolution. Then, 0.80 g hydrochloric acid 37% in water (0.008 mol) were added and the reaction mixture was heated to the reflux temperature and kept under these conditions for eight hours. At the end of the reaction, the temperature was brought to 15° C., a 30% ammonia solution was added up to pH 8 and the resultant solid was filtered. To the mother liquor 10 ml toluene were added, the mixture was washed with water (2×5 ml) and the collected organic phases were concentrated to residue by distillation under vacuum to give 1 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2-methyl-propanoate.
In a reaction flask 1.0 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.004 mol), 5 ml methanol, 2.73 g zinc bromide (0.01 mol) were charged and the reaction mixture was kept under stirring up to complete dissolution. Then, 2.0 g hydrobromic acid 33% solution in acetic acid (0.008 mol) were added and the reaction mixture was heated to the reflux temperature and kept under these conditions for eight hours. At the end of the reaction, the temperature was brought to 15° C., a 30% ammonia solution was added up to pH 8 and the resultant solid was filtered. To the mother liquor 10 ml toluene were added, the mixture was washed with water (2×5 ml) and the collected organic phases were concentrated to residue by distillation under vacuum to give 1.1 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2-methyl-propanoate.
In a reaction flask 10 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.04 mol), 50 ml methanol, 27.4 g zinc bromide (0.12 mol) were charged and the reaction mixture was kept under stirring up to complete dissolution. Then, 13.5 g hydrobromic acid 48% solution in water (0.08 mol) were added and the reaction mixture was heated to the reflux temperature and kept under these conditions for eight hours. At the end of the reaction, the temperature was brought to 15° C., a 30% ammonia solution was added up to pH 8 and the resultant solid was filtered. To the mother liquor 100 ml toluene were added, the mixture was washed with water (2×20 ml) and the collected organic phases were concentrated to residue by distillation under vacuum to give 11 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2-methyl-propanoate.
In a reaction flask 0.8 g zinc (0.01 mol), 5 ml methanol, 7.46 g hydrobromic acid 33% solution in acetic acid (0.03 mol) were charged and the temperature was brought to 45° C. up to complete dissolution. Then. 1.0 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.004 mol) were added and the temperature was brought to the reflux temperature of the solvent and kept under these conditions for eight hours. At the end of the reaction, the temperature was brought to 15° C., a 30% ammonia solution was added up to pH 8 and the resultant solid was filtered. To the mother liquor 10 ml toluene were added, the mixture was washed with water (2×5 ml) and the collected organic phases were concentrated to residue by distillation under vacuum to give 1.1 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2-methyl-propanoate.
In a reaction flask 10 g of methyl 2-(4-(2-methoxytetrahydrofuran-2-yl)phenyl)-2methyl-propanoate (0.038 mol) and 20 ml toluene were charged. To the resultant solution 17.6 g hydrobromic acid 33% soiution in acetic acid (0.072 mol) were added dropwise and the reaction mixture was kept under stirring at the temperature of 25° C. for 10 hours. At the end of the reaction, 30 ml toluene were added, the mixture was washed with a saturated sodium bicarbonate solution (1×30 ml) and water (2×20 ml). The collected organic phases were concentrated to residue by distillation under vacuum to give 10.5 g di methyl 4-(4-bromo-1-oxybutyl)-α,α-dimethylphenylacetate.
1H-NMR (CDCl3, 300 MHz): δ 7.96 (d, 2H), 7.42 (d, 2H), 3.58 (s, 3H), 3.54 (t, 2H), 3.17 (t, 2H), 2.99 (m, 2H), 1.58 (s, 6H).
In a reaction flask 1.0 g of methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.004 mol), 2 ml toluene, 1.36 g hydrobromic acid 48% solution in water (0.008 mol) were charged and the reaction mixture was kept under stirring at the temperature of 25° C. for 15 hours. At the end of the reaction, 3 ml toluene were added, the mixture was washed with a saturated sodium bicarbonate solution (1×3 ml) and water (2×2 ml). The collected organic phases were concentrated to residue by distillation under vacuum and purified by column chromatography to give 0.45 g di methyl 4-(4-bromo-1-oxybutyl)-α,α-dimethylphenylacetate.
In a reaction flask 5 g methyl 4-(4-bromo-1-oxybutyl)-α,α-dimethylphenylacetate (0.15 mol), 25 ml toluene, 4.08 g azacyclonol (0.015 mol), 10 ml water, 1.53 g sodium bicarbonate (0018 mol) and 0.25 g potassium iodide (0.0015 mol) were charged, the reaction mixture was brought to the reflux temperature and kept under these conditions for 20 hours. At the end of the reaction, the temperature was brought to 25° C., the separated organic phase was concentrated to residue by distillation under vacuum to give 7 g methyl 2-(4-(4-(4-(hydroxy-diphenylmethyl)piperidin-1-yl)-1-oxybutyl)phenyl)-2-methyl-propanoate.
In a reaction flask, 7.0 g methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1-oxybutyl)phenyl)-2-methyl-propanoate (0.01 mol), 20 ml methanol, 2.0 g sodium hydroxide 30% solution in water (0.015 mol) were charged, the temperature were brought to the reflux temperature of the solvent and the reaction mixture was kept under these conditions for seven hours. At the end of the reaction, the temperature was brought to 10° C., 0.2 g sodioborohydride (0.005 mol) were charged and the temperature was brought to 40° C. and kept under these conditions for fifteen hours.
At the end of the reaction, the temperature was brought to 15° C. and 1.2 g acetic acid (0.02 mol) and 10 ml water were charged. The suspension was filtered and the solid was washed with a 1:1 water/methanol mixture (2×4 ml). The solid was dried under vacuum at 40° C. obtaining 6.7 g fexofenadine.
In a reaction flask, 7 g methyl 4-(4-bromo-1-oxybutyl)-α,α-dimethylphenylacetate (0.02 mol), 35 ml methanol, 0.2 g sulfuric acid (0.002 mol) and 3.4 g trimethylorthoformate (0.032 mol) were charged, the solution was heated to the reflux temperature and kept under these conditions for ten hours. At the end of the reaction, the temperature was brought to 25° C. and 6.1 g sodium methoxide 30% solution hi methanol (0.034 mol), 40 ml methylene chloride were added and the organic phase was washed with water (2×10 ml). The collected organic phases were concentrated to residue by distillation under vacuum to give 7.2 g methyl 2-(4-(4-bromo-1 1-dimethoxybutyl)phenyl)-2-methyl-propanoate.
1H-NMR (CDCl3, 300 MHz): δ 7.37 (d, 2H), 7.29 (d, 2H), 3.63 (s, 3H), 3.18 (m, 4H), 2.02 (m, 2H), 1.55 (s, 6H).
13C-NMR (CDCl3, 300 MHz): δ 177.25 (C), 144.24 (C), 138.94 (C), 126.13 (CH), 125.39 (CH), 103.02 (C), 52.25 (CH3), 48.73 (CH3), 46.41 (C), 35.89 (CH2), 33.74 (CH2), 27.13 (CH2), 26.64 (CH3).
In a reaction flask 5 g methyl 2-(4-(4-bromo-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoate (0.013 mol), 25 ml toluene, 3.57 g azacyclonol (0.013 mol), 10 ml water, 1.30 g sodium bicarbonate (0.016 mol) and 0.21 g potassium iodide (0.0013 mol) were charged, the reaction mixture was heated to the reflux temperature and kept under these conditions for 20 hours. At the end of the reaction, the temperature was brought to 25° C., the separated organic phase was concentrated to residue by distillation under vacuum to give 7.0 g methyl 2-(4-(4-(4-(hydroxy-diphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoate.
1H-NMR (CDCl3, 300 MHz): δ 7.37 (m, 4H), 7.29 (m, 8H), 3.63 (s, 3H), 3.15 (s, 6H), 3.01 (m, 2H), 2.71 (m, 5H), 1.88 (m, 2H), 1.55 (s, 6H), 1.36 (m, 2H).
In a reaction flask 7.0 g methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methylpropanoate (0.01 mol), 35 ml methanol, 5 ml water, 1.5 g sulfuric acid 96% (0.015 mol) were charged, the temperature was brought to 40° C. and the reaction mixture was kept under these conditions for twelve hours. At the end of the reaction, the temperature was brought to 15° C., 20 ml water and ammonia 30% solution up to pH 8 were added, the resultant solid was filtered and dried in oven at 40° C. under vacuum to give 5.8 g methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methyl-propanoate.
The synthesis of fexofenadine starting from methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoyl)phenyl)-2-methyl-propanoate, as prepared in example 12, was carried out following the procedure reported in example 9.
In a reaction flask 20 g hydrobromic acid 33% in acetic acid (0.082 mol) and 10 g methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.04 mol) were charged keeping the temperature at 35° C. and the reaction mixture was kept under these conditions for four hours. At the end of the reaction, the temperature was brought to 20° C., 50 ml toluene were added and the organic phase was washed with water (3×25 ml). The collected organic phases were concentrated to residue by distillation under vacuum to give 10.6 g methyl 4-(4-bromo-1-oxybutyl)-α,α-dimethylphenylacetate.
1H-NMR (CDCl3, 300 MHz): δ 7.96 (d, 2H), 7.42 (d, 2H), 3.58 (s, 3H), 3.54 (t, 2H), 3.17 (t, 2H), 2.99 (m, 2H), 1.58 (s, 8H).
In a reaction flask 102 g methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methylpropanoate (0.18 mol), 270 ml methanol and 40.8 g sodium hydroxide 30% solution (0.31 mol) were charged, the reaction mixture was heated to the reflux temperature of the solvent and kept under these conditions for four hours. At the end of the reaction, the temperature was brought to 20° C. and 18.4 g glacial acetic acid (0.31 mol) were added. The precipitated solid was filtered and washed with methanol (2×30 ml) and dried in oven under vacuum at 40° C. up to constant weight to give 80 g 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoic acid.
1H-NMR (DMSO, 300 MHz): δ 7.48 (d, 4H), 7.31 (s, 4H), 7.23 (m, 4H), 7.10 (m, 2H), 3.02 (s, 6H), 2.60 (d, 2H), 2.40 (m, 1H), 2.03 (m, 2H), 1.77 (m, 4H), 1.42 (s, 6H), 1.36 (m, 2H), 1.68 (m, 2H), 0.99 (m, 2H).
In a reaction flask, 10 g 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoic acid (0.018 mol), 30 ml methanol and 2 g hydrochloric acid 37% solution (0.018 mol) were charged, the reaction mixture was heated to 25° C. and kept under these conditions for one hour. At the end of the reaction, 5.0 g sodium hydroxide 30% solution in water (0.038 ml) and 0.4 g sodioborohydride (0.010 mol) were charged, the temperature was brought to 40° C. and the reaction mixture was kept under these conditions for ten hours. At the end of the reaction, the temperature was brought to 13° C. and 1.2 g acetic acid (0.02 mol) and 10 ml water were charged. The is suspension was filtered and the solid was washed with a 1:1 water/methanol mixture (2×4 ml). The solid was dried under vacuum at 40° C. obtaining 9 g fexofenadine.
In a reaction flask, 50 g methyl 2-(4-(4-hydroxybut-1-inyl)-2-methyl-propanoate (0.203 mol), 50 ml toluene were charged, the temperature was brought to 40° C. and 50.01 g hydrochloric acid 37% solution in water (0.507 mol) were charged in eight hours and the reaction mixture was kept under these conditions for about four hours. At the end of the reaction, the temperature was brought to 25° C., 100 ml toluene were added and the mixture was washed with water (4×50 ml) up to a pH value of about 4. The collected organic phases were concentrated to residue by distillation under vacuum to give 54 g methyl 4-(4-chloro-1-oxybutyl)-α,α-dimethylphenylacetate.
In a reaction flask, 25 g methyl 4-(4-chloro-1-oxybutyl)-α,α-dimethylphenylacetate (0.088 mol), 50 ml methanol, 11.27 g trimethylorthoformate (0.106 mol), 0865 g sulfuric acid (0.009 mol) were charged, the solution was heated to the reflux temperature and kept under these conditions for three hours. At the end of the reaction, the temperature was brought to 25° C. and 1.58 g sodium methoxide 30% solution in methanol were added, the solvent was removed by distillation under vacuum and 100 ml toluene were added. After washing with water (1×50 nil) the collected organic phases were concentrated to residue by distillation under vacuum to give 34 g methyl 2-(4-(4-chloro-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoate.
1H-NMR (CDCl3, 300 MHz): δ 7.40 (m, 2H), 7.37 (m, 2H), 3.64 (s, 3H), 3.37 (t, 2H), 3.14 (s, 6H), 2.01 (m, 2H), 1.57 (s, 6H), 1.45 (m, 2H).
In a reaction flask 34 g methyl 2-(4-(4-chloro-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoate (0.079 mol), 130 ml toluene, 21.17 g azacyclonol (0.079 mol), 10 ml water, 7.39 g sodium bicarbonate (0.088 mol) and 0.050 g potassium iodide (0.003 mol) were charged, the reaction mixture was heated to the reflux temperature and kept under these conditions for 15 hours. At the end of the reaction, the temperature was brought to 25° C., the separated organic phase was concentrated to residue by distillation under vacuum to give 50 g methyl 2-(4-(4-(4-(hydroxy-diphenylmethyl)piperidin-1-yl)-1,1-dimethoxybutyl)phenyl)-2-methyl-propanoate.
1H-NMR (CDCl3, 300 MHz): δ 7.37 (m, 4H), 7.29 (m, 8H), 3.63 (s, 3H), 3.15 (s, 6H), 3.01 (m, 2H), 2.71 (m, 5H), 1.88 (m, 2H), 1.55 (s, 6H), 1.36 (m, 2H).
| Number | Date | Country | Kind |
|---|---|---|---|
| MI2012A000329 | Mar 2012 | IT | national |
| MI2012A000589 | Apr 2012 | IT | national |
